Equities research analysts expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to announce sales of $119.16 million for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Lexicon Pharmaceuticals’ earnings. The lowest sales estimate is $26.15 million and the highest is $167.71 million. Lexicon Pharmaceuticals reported sales of $294.45 million in the same quarter last year, which would suggest a negative year over year growth rate of 59.5%. The company is expected to announce its next quarterly earnings report on Thursday, November 5th.
On average, analysts expect that Lexicon Pharmaceuticals will report full-year sales of $147.82 million for the current fiscal year, with estimates ranging from $43.45 million to $184.87 million. For the next fiscal year, analysts expect that the business will report sales of $7.98 million, with estimates ranging from $590,000.00 to $15.37 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.02). Lexicon Pharmaceuticals had a return on equity of 50.16% and a net margin of 12.26%. The firm had revenue of $9.16 million during the quarter, compared to analysts’ expectations of $8.70 million.
Hedge funds have recently bought and sold shares of the business. Investors Financial Group LLC purchased a new position in Lexicon Pharmaceuticals during the 2nd quarter valued at about $31,000. Diversified Trust Co purchased a new position in shares of Lexicon Pharmaceuticals during the second quarter worth about $35,000. Jane Street Group LLC purchased a new position in shares of Lexicon Pharmaceuticals during the second quarter worth about $36,000. ProShare Advisors LLC grew its holdings in shares of Lexicon Pharmaceuticals by 33.0% during the second quarter. ProShare Advisors LLC now owns 22,702 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 5,629 shares in the last quarter. Finally, UBS Group AG grew its holdings in shares of Lexicon Pharmaceuticals by 63.2% during the second quarter. UBS Group AG now owns 26,891 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 10,416 shares in the last quarter.
LXRX traded down $0.04 during trading hours on Tuesday, hitting $1.47. The stock had a trading volume of 437,582 shares, compared to its average volume of 1,179,828. The company’s fifty day simple moving average is $1.57 and its 200 day simple moving average is $1.84. Lexicon Pharmaceuticals has a 1 year low of $1.37 and a 1 year high of $5.33. The stock has a market cap of $157.45 million, a PE ratio of 7.74 and a beta of 1.38. The company has a quick ratio of 2.48, a current ratio of 2.52 and a debt-to-equity ratio of 4.28.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Featured Article: What does a dividend yield signify to investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.